Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience

The standard management for relapsed or refractory classical Hodgkin lymphoma (cHL) is salvage therapy followed by autologous stem cell transplantation (ASCT). This strategy allows almost 50% of patients to be cured. Post‐ASCT maintenance treatment with brentuximab vedotin (BV) confers improved prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Massaro, Fulvio, Pavone, Vincenzo, Stefani, Piero Maria, Botto, Barbara, Pulsoni, Alessandro, Patti, Caterina, Cantonetti, Maria, Visentin, Andrea, Scalzulli, Potito Rosario, Rossi, Andrea, Galimberti, Sara, Cimminiello, Michele, Gini, Guido, Musso, Maurizio, Sorio, Marco, Arcari, Annalisa, Zilioli, Vittorio Ruggero, Luppi, Mario, Mannina, Donato, Fabbri, Alberto, Pietrantuono, Giuseppe, Annibali, Ombretta, Tafuri, Agostino, Prete, Eleonora, Mulè, Antonino, Barbolini, Elisa, Marcheselli, Luigi, Luminari, Stefano, Merli, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298220/
https://www.ncbi.nlm.nih.gov/pubmed/34694649
http://dx.doi.org/10.1002/hon.2939

Ejemplares similares

Ejemplares similares